STAT+: “This is not a cure”: Consensus begins to emerge on new Alzheimer’s drug
NEW YORK — A consensus may be emerging about how to prescribe the new Alzheimer’s drug lecanemab, according to remarks made by both a critic of other Alzheimer’s medicines and the CEO of the company that developed it.
The comments were made at a STAT event on Monday night.
